Ron Alfa
@ron_alfaCEO/Co-founder, @NOETIK_AI | Previously SVP, Head of Research @RecursionPharma $RXRX | @StanfordMed Neuroscience MD-PhD | @PDSoros | Build the Future
Similar User
@RecursionChris
@viswacolluru
@RecursionPharma
@ameekapadia
@bitsinbio
@patricksmalone
@lifeschemistry
@velvetatom
@Atelfo
@zavaindar
@davidycli
@AlfredoAndere
@pablolubroth
@AltitudeLab
@glebkuz
1/ @NOETIK_ai team are live at #SITC24 showing off new biological discoveries using our foundation models for human cellular and tissue biology. Come along for a tour:
Cooking high heat.
Founder mode is on a lower heat setting in biotech than in tech today but it’s still cooking. Don’t sleep on it
100%. Pharmacology is commoditized.
This is 100% coming to all of biotech, if not already here Also not happening just at early clinical stage … Discovery is similar. In China, standing start to DC with desired molecule target profile in ~18 mo For US biotechs there had better be some novel biology or more…
Today we report Evo, a generalist foundation model for biology, on the cover of @ScienceMagazine Trained on billions of DNA nucleotides, Evo was designed to capture two key aspects of biology: the multi-modality of the central dogma and the multi-scale nature of evolution.
A new Science study presents “Evo”—a machine learning model capable of decoding and designing DNA, RNA, and protein sequences, from molecular to genome scale, with unparalleled accuracy. Evo’s ability to predict, generate, and engineer entire genomic sequences could change the…
Beat me to it.
My investment thesis for 2025 after today: monoclonal antibodies for measles, polio, and other preventable diseases
Breakthroughs in biology World Models at @NOETIK_ai to simulate patient biology for drug discovery and translation.
1/ This is the next chapter of a story about courageous patients and their families, of multidisciplinary teamwork, and hard-fought steps forward to effective therapy for #DIPG #DMG, a universally lethal cancer of the brain and spinal cord. 🧵nature.com/articles/s4158…
Today the emotions are many but words are few. I’ll save the latter for a longer post soon. Let’s go @lifeschemistry ! 🚀
This one is special… We have advanced our first drug into Phase 1 clinical trials! ENV-294 is a first-in-class small molecule with exciting potential to treat atopic dermatitis (commonly known as eczema) – an underserved and devastating inflammatory condition that impacts more…
Training this week: single cell spatial transcriptomics + tumor whole exome seq, 1000 patients 500M parameters, 96 H100s
Our slack is often crazy awesome images with understated comments. “The re-scans look pretty good.”
United States Trends
- 1. Jake Paul 1,01 Mn posts
- 2. #Arcane 223 B posts
- 3. Jayce 53,3 B posts
- 4. Good Saturday 27,2 B posts
- 5. #SaturdayVibes 3.281 posts
- 6. #saturdaymorning N/A
- 7. Serrano 249 B posts
- 8. #PlutoSeriesEP5 150 B posts
- 9. Pence 82 B posts
- 10. AioonMay Limerence 124 B posts
- 11. #SaturdayMood 1.698 posts
- 12. Vander 17,5 B posts
- 13. IT'S GAMEDAY 2.477 posts
- 14. Caturday 7.780 posts
- 15. maddie 21,4 B posts
- 16. WOOP WOOP 1.439 posts
- 17. John Oliver 14,7 B posts
- 18. Fetterman 37 B posts
- 19. $XRP 85,4 B posts
- 20. Father Time 10,6 B posts
Who to follow
-
Chris Gibson
@RecursionChris -
Viswa Colluru
@viswacolluru -
Recursion
@RecursionPharma -
Amee Kapadia
@ameekapadia -
Bits in Bio
@bitsinbio -
Patrick Malone, MD PhD
@patricksmalone -
Enveda
@lifeschemistry -
Tess van Stekelenburg
@velvetatom -
Alex Telford
@Atelfo -
Zavain Dar
@zavaindar -
David Li
@davidycli -
Alfredo Andere
@AlfredoAndere -
Pablo Lubroth
@pablolubroth -
Altitude Lab
@AltitudeLab -
Gleb Kuznetsov
@glebkuz
Something went wrong.
Something went wrong.